| Literature DB >> 33370810 |
Ben Jiahe Gu1, David K Kung2, Han-Chiao Isaac Chen2.
Abstract
Cell therapy has been widely recognized as a promising strategy to enhance recovery in stroke survivors. However, despite an abundance of encouraging preclinical data, successful clinical translation remains elusive. As the field continues to advance, it is important to reexamine prior clinical trials in the context of their intended mechanisms, as this can inform future preclinical and translational efforts. In the present work, we review the major clinical trials of cell therapy for stroke and highlight a mechanistic shift between the earliest studies, which aimed to replace dead and damaged neurons, and later ones that focused on exploiting the various neuromodulatory effects afforded by stem cells. We discuss why both mechanisms are worth pursuing and emphasize the means through which cell replacement can still be achieved. © Congress of Neurological Surgeons 2020.Entities:
Keywords: Cell therapy; Clinical trial; Stem cells; Stroke; Tissue engineering; Tissue therapy
Mesh:
Year: 2021 PMID: 33370810 PMCID: PMC7955967 DOI: 10.1093/neuros/nyaa531
Source DB: PubMed Journal: Neurosurgery ISSN: 0148-396X Impact factor: 4.654